SLAM
ACAD icon

Swiss Life Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Swiss Life Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
+8,636
New +$190K ﹤0.01% 1478
2026
Q1 		– Sell
-12,325
Closed -$329K – 1507
2025
Q4 		$329K Buy
+12,325
New +$295K ﹤0.01% 981

Other funds holding ACAD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swiss Life Asset Management's ACAD Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 8,636 shares worth $218K. The stake represents ﹤0.01% of the portfolio and ranks #1478 among its holdings. This is a return to the name: Swiss Life Asset Management previously reported a position in ACAD as recently as Q4 2025.

Swiss Life Asset Management first reported a position in ACAD in Q4 2025 and has held it in 2 quarters since. The position peaked at $329K in Q4 2025. 204 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Swiss Life Asset Management held 8,636 shares of Acadia Pharmaceuticals worth $218K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Swiss Life Asset Management position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1478 holding.
  • Swiss Life Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Swiss Life Asset Management's Acadia Pharmaceuticals position peaked at $329K in Q4 2025.
  • 204 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.